Seagen touts full PhII Tukysa da­ta as it plots col­orec­tal can­cer ex­pan­sion

As ru­mors of a Mer­ck buy­out con­tin­ue to swirl around Seagen, the big Seat­tle biotech is charg­ing ahead with new da­ta for its can­cer drug Tukysa.

Seagen re­port­ed full re­sults Sat­ur­day from a Phase II study mea­sur­ing Tukysa’s ef­fec­tive­ness in sec­ond-line HER2-pos­i­tive metasta­t­ic col­orec­tal can­cer, af­ter re­veal­ing a 38.1% over­all re­sponse rate in May. The new da­ta show Tukysa, in com­bi­na­tion with Her­ceptin, in­duced a pro­gres­sion-free sur­vival of 8.2 months and over­all sur­vival of 24.1 months.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER